medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 6

<< Back Next >>

Ann Hepatol 2017; 16 (6)

Fibrogenic/Angiogenic Linker for Non-Invasive Assessment of Hepatic Fibrosis Staging in Chronic Hepatitis C Among Egyptian Patients

Toson EL-Shahat A, Shiha GE, Abdelgaleel AE

Language: English
References: 45
Page: 862-873
PDF size: 184.28 Kb.


ABSTRACT

Background and rationale for the study. Liver biopsy is the golden standard for staging liver fibrosis, but it may be accompanied by complications. Because of this complication, the aim of this study is to evaluate a simple noninvasive score to assess hepatic fibrosis in chronic hepatitis C genotype 4 patients which is very may have an important in diagnosis and therapeutic decision. This score [HA vascular (HAV) score] is a combination of direct markers [hyaluronic acid (HA) and vascular endothelial growth factor (VEGF)] and indirect markers [aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR)]. Results. Samples were collected from 220 patients (F0-F4): an estimated group (n = 120) and a validated group (n = 100). HA and VEGF levels, HCV RNA, liver function tests, platelet counts were assayed, Fibroscan was done and liver biopsy was taken and the stage of liver fibrosis and the grade of inflammatory activity was calculated according to Metavir score system. HA vascular (HAV) score = -35.1 + 0.14 (HA) (ng/L) + 0.03 (VEGF) (pg/mL) + (-6.7) [AAR (AST/ALT ratio)]. The HAV score produced areas under curve of 0.979 and 0.994 for significant (F2-F4) and advanced fibrosis (F3-F4) (cut off = 0.583 and 6.3, respectively). Surprisingly, the validation study of this score gave very good values of AUCs i.e. 0.990, 0.996 and 0.995 for significant, advanced and liver cirrhosis. Conclusions: Our developed score can not only help to assess liver fibrosis staging effectively but also avoid the invasiveness and the limitations of liver biopsy in Egyptian hepatitis C virus patients.


REFERENCES

  1. Abdel-Misih SRZ, Bloomston M. Liver Anatomy. Surg Clin North Am 2010; 90: 643-63.

  2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbial Infect 2011; 17: 107-15.

  3. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26: 401-12.

  4. Mohamed AA, Elbedewy TA , El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A global view. World J Hepatol 2015; 7: 2676-80.

  5. Gupta E, Bajpai M, Choudhary A. Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays. Asian J Transfus Sci 2014; 8: 19-25.

  6. Baiocchini A, Montaldo C, Conigliaro A, Grimaldi A, Correani V, Mura F, Ciccosanti F, et al. Extracellular Matrix Molecular Remodeling in Human Liver Fibrosis Evolution. PLoS One 2016; 11: e0151736.

  7. Klaas M, Kangur T, Viil J, Mäemets-Allas K, Minajeva A, Vadi K, Antsov M, et al. The alterations in the extracellular matrix composition guide the repair of damaged liver tissue. Scientific Reports 2016; 6: 27398.

  8. Saleh HA, Abu-Rashed AH. Liver biopsy remains the gold standard for evaluation of chronic hepatitis and fibrosis. J Gastrointestin Liver Dis 2007; 16: 425-6.

  9. Wilkins T, Akhtar M, Gititu E, Jalluri C, Ramirez J. Diagnosis and management of hepatitis C. Am Fam Physician 2015; 91: 835-42.

  10. Afdhal NH, Nunes D. Evaluation of liver fibrosis. Am J Gastroenterol 2004; 99: 1160-74.

  11. Lurie y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol 2015; 21: 11567-83.

  12. Colecchia A, Marasco G, Taddia M, Montrone L, Eusebi LH, Mandolesi D, Schiumerini R, et al. Liver and spleen stiffness and other noninvasive methods to assess portal hypertension in cirrhotic patients: a review of the literature. Eur J Gastroenterol Hepatol 2015; 27: 992-1001.

  13. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36: S57-S64.

  14. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12: 3682-94.

  15. Straub BK, Schirmacher P. Pathology and biopsy assessment of nonalcoholic fatty liver disease. Dig Dis 2010; 28: 197-202.

  16. Toson EA, Shiha GE, EL-Saied EH, Samir W, ELbasiony M, Shoieb DA. CAN YKL-40 improve the diagnostic power of non-invasive fibrogenic staging in chronic hepatitis B virus infected patients? EJPMR 2016; 3: 70-8.

  17. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Medicine 2003; 9: 677-84.

  18. Toson EA, Shiha GE, El-mezayen HA, Samir W, El-khininy MM. Noninvasive estimation of liver fibrosis in biopsy-proven hepatitis C virus-infected patients: angiogenic fibrogenic link. Eur J Gastroenterol Hepatol 2017; 29: 199-207.

  19. Thurston G. Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell and Tissue Research 2003; 314: 61-8.

  20. Halfon P, Bourlière M, Pénaranda G, Deydier R, Renou C, Botta-Fridlund D, Tran A, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005; 4: 6.

  21. Salcedo X, Medina J, Sanz-Cameno P, García L, Samuel B, Vilchez M, Borque M, López-Cabrera M, et al. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 2005; 42: 697-701.

  22. Tahergorabi Z, Khazaei M. Imbalance of Angiogenesis in Diabetic Complications: The Mechanisms. In J Prev Med 2012; 3: 827-38.

  23. Sterling RK, Lissen E, Clumeek N, Sola R, Correa MC, Montaner J, Sulkowski M, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/ HCV co infection. Hepatology 2006; 43: 1317-25.

  24. Ahmad W, Ijaz B, Javed F, Gull S, Kausar H, Sarwar MT, Asad S, et al. A comparison of four fibrosis indexes in chronic HCV: Development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterology 2011; 10: 1186-471.

  25. Geramizadeh B, Janfeshan K, Saberfiroozi M. Serum Hyaluronic Acid as a Noninvasive Marker of Hepatic Fibrosis in Chronic Hepatitis B. Saudi J Gastroenterol 2008; 14: 174-7.

  26. Bota S, Sirli R, Sporea I, Focsa M, Popescu A, Danila M, Strain M, et al. A new scoring system for prediction of fibrosis in chronic hepatitis C. Hepat Mon 2011; 11: 548-55.

  27. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.

  28. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008; 372: 321-32.

  29. Montazeri G, Estakhri A, Mohamadnejad M, Nouri N, Montazeri F, Mohammad kani A, Derakhshan M, et al. Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol 2005; 5: 32.

  30. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-54.

  31. Dehghani SM, Imanieh MH, Haghighat M, Malekpour A, Falizkar Z. Etiology and Complications of Liver Cirrhosis in Children: Report of a Single Center from Southern Iran. Middle East J Dig Dis 2013; 5: 41-6.

  32. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection. Practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.

  33. Li J, Xu Y, Jiao H, Wang W, Mei Z, Chen G. Sumoylation of hypoxia inducible factor-1 and its significance in cancer. Science China Life Sciences 2014; 57: 657-64.

  34. Xu B, Broome U, Uzunel M, Nava S, Ge X, Nava S, Ge X, et al., Capillarization of Hepatic Sinusoid by Liver Endothelial Cell-Reactive Autoantibodies in Patients with Cirrhosis and Chronic Hepatitis. Am J Pathol 2003; 163: 1275-89.

  35. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148: 399-408.

  36. Stravitz RT, Lisman T, Luketic VA, Sterling RK, Puri P, Fuchs M, Ibrahim A, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012; 19: 129-36

  37. Tan BAZ, Messi WZM, Laura M, Akiva M, Osvaldo D. Pericytes at the intersection between tissue regeneration and pathology. Clinical Science 2015; 128: 81-93.

  38. Risau W, Flamme I. Vasculogenesis. Annual Review of Cell and Developmental Biology 1995; 11: 73-91.

  39. Tahergorabi Z, Khazaei M. Imbalance of Angiogenesis in Diabetic Complications: The Mechanisms. Int J Prev Med 2012; 3: 827-38.

  40. Liang XH, Zheng H. Value of simultaneous determination of serum hyaluronic acid, collagen type IV and the laminin level in diagnosing liver fibrosis. Huang Yi Ke Da Xue Xue Bao 2002; 28: 67-8.

  41. Duval F, Moreno-Cuevas JE, González-Garza MT, Maldonado- Bernal C, Cruz-Vega DE. Liver Fibrosis and Mechanisms of the Protective Action of Medicinal Plants Targeting Inflammation and the Immune Response. Int J Inflam 2014; 2015; 14 pages.

  42. Iacovacci S, Bertolini L, Manzin A, Valli MB, Battaglia M, Ponzetto A, Serafino A, et al. Quantitation of hepatitis C virus RNA production in two human bone marrow-derived Bcell lines infected in vitro. Research in Virology 1997; 148: 147-51.

  43. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol 2001; 280: 1358-66.

  44. Albeiroti S, Soroosh A, de la Motte CA. Hyaluronan's Role in Fibrosis: A Pathogenic Factor or a Passive Player? Biomed Res Int 2015; 2015: 790203.

  45. Thomas S, Vanuystel J, Gruden G, Rodríguez V, Burt D, Gnudi L, Hartley B, et al. Vascular Endothelial Growth Factor Receptors in Human Mesangium in Vitro and in Glomerular Disease. JASN 2000; 11: 71236-43.




2020     |     www.medigraphic.com